A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
Status:
Terminated
Trial end date:
2020-03-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effects of CNP520 on cognition, global clinical
status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for
the onset of clinical symptoms of AD based on their age, APOE genotype and elevated amyloid.